FDA Clears KT501 for U.S. Autoimmune Study
Kali Therapeutics disclosed FDA clearance of KT501, a masked CD19xBCMAxCD3 trispecific T-cell engager, enabling U.S. development for B-cell-mediated autoimmune disease. The program is already in a Phase Ia rheumatoid-arthritis study in Australia. Dual B-lineage…
